Q2 2025 Management View Co-CEO Justin B. Klee highlighted "meaningful progress across our clinical programs" in the first half of 2025, emphasizing Avexitide as the lead asset, which is an ...

Day One Biopharmaceuticals poised for growth with OJEMDA success and FIREFLY-2 catalysts. See here to know why we are bullish ...